Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Overview
- Founded
-
1996
- Status
-
Public
- Employees
-
817
- Stock Symbol
-
01349
- Investments
-
1
- Share Price
-
$0.43
- (As of Thursday Closing)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical General Information
Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Contact Information
Primary Industry
Drug Discovery
Stock Exchange
HKG
Primary Office
- No.308 Cailun Road
- Z.J.Hi-tech Park
- Shanghai, 201210
- China
+86 00000000000
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.43 | $0.41 | $0.32 - $0.49 | $1.2B | 1.03B | 335K | $0.02 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 1,020,693 | 1,547,673 | 325,392 | 479,773 |
| Revenue | 156,709 | 176,599 | 120,690 | 148,965 |
| EBITDA | 23,023 | 42,447 | 33,709 | 44,917 |
| Net Income | 17,309 | 33,033 | 23,834 | 32,904 |
| Total Assets | 403,166 | 436,324 | 382,762 | 223,649 |
| Total Debt | 4,271 | 4,905 | 3,014 | 22,167 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Haibo Wang | Chairman, Executive Director & General Manager | ||
| Yan Xue | Company Secretary & Authorized Representative |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Chairman, Executive Director & General Manager | 000 0000 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 22-Feb-2017 | 000000000 | 000 | Biotechnology |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
35.09 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 455
Rank
00.0
Percentile
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000000 | 22-Feb-2017 | 000000000 | 000 | Completed |
|